A Phase 1 interventional study of LY2940680 in Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Neoplasm Metastasis by Eli Lilly and Company — 7 open to participants now, 16 under way, 7 of them phase 3. Neoplasm Metastasis · Eli Lilly and Company.
Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 56th largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2013, is one of 43 in phase 1, and was the 36th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.
Browse Neoplasm Metastasis studies →7 of the 72 studies in Neoplasm Metastasis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Brazil and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Austria and 24 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 16 · Phase 3 10 · Phase 4 1
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 50 across 3,270 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 77 across the 66 interventional studies, 1,610 across the 1 observational. Of the 54 that completed or were terminated, 37 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
5 of the studies in Neoplasm Metastasis by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT05614739Eli Lilly and CompanyFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | 2027-06 |
| NCT06561685Eli Lilly and CompanyA Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles. Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met.
Drug: LY2940680
Administered orally
Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT)
DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and meets any one of the following criteria based on NCI CTCAE,version 4.0): Grade(Gr) 3 nonhematological toxicity(tox) with exceptions for made for nausea(ns),vomiting(vm),constipation(cp),diarrhea(dr),fatigue(ft),anorexia(an),alopecia or electrolyte-abnormality(eab) that is manageable with appropriate care.If \>Gr 3 ns,vm,cp,dr,ft,an,or eab persists for\>2 days with maximal supportive intervention,the event was declared a DLT.Transient(≤5 days) Gr 3 liver enzyme elevations,without evidence of other hepatic injury.Gr 3 thrombocytopenia(throm) requiring platelet transfusion or Gr 4 throm.Gr 4 neutropenia of \>5 days duration.Febrile neutropenia(ANC\<1,000/mm3 with a single temperature(temp) of \>38.3 degrees C or a sustained temp of ≥38 degrees C for more than one hour).Tox requiring dose omissions of \>5 days or significant \& deemed by the primary investigator(PI) \& sponsor(sp) to be dose limiting .
Time frame: Cycle 1 (28 Days)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556)
Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556).
Time frame: Cycle1 Day1: Predose, 0.5,1,2,4, 6, 8, 10-12 hours; Cycle 1 Day15: Predose, 0.5,1,2,4, 6, 8, 10-12 hours
Pharmacokinetics (PK): Area Under the Concentration Time Curve From 0 to 24 Hours (AUC[0-24]) of LY2940680 and a Major Metabolite of LSN3185556
Pharmacokinetics (PK): Area Under the Concentration time Curve From 0 to 24 Hours (AUC\[0-24\]) of LY2940680 and a Major Metabolite of LSN3185556.
Time frame: Cycle1 Day1: Predose, 0.5,1,2,4, 6, 8, 10-12 hours; Cycle 1 Day15: Predose, 0.5,1,2,4, 6, 8, 10-12 hours
Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size (\<10 millimeter \[mm\] short axis). PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.
Time frame: Baseline Until Disease Progression or Death Due to Any Cause (Up to 29 Months)
Pharmacodynamic (PD): Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin
Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin.
Time frame: Baseline, Cycle 1 Day15
| Milestone | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| Started | 3 | 3 | 13 |
| Received at least one dose of study drug | 3 | 3 | 13 |
| Completed | 3 | 3 | 9 |
| Not completed | 0 | 0 | 4 |
| Withdrew: Progressive disease | 0 | 0 | 4 |
DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and meets any one of the following criteria based on NCI CTCAE,version 4.0): Grade(Gr) 3 nonhematological toxicity(tox) with exceptions for made for nausea(ns),vomiting(vm),constipation(cp),diarrhea(dr),fatigue(ft),anorexia(an),alopecia or electrolyte-abnormality(eab) that is manageable with appropriate care.If \>Gr 3 ns,vm,cp,dr,ft,an,or eab persists for\>2 days with maximal supportive intervention,the event was declared a DLT.Transient(≤5 days) Gr 3 liver enzyme elevations,without evidence of other hepatic injury.Gr 3 thrombocytopenia(throm) requiring platelet transfusion or Gr 4 throm.Gr 4 neutropenia of \>5 days duration.Febrile neutropenia(ANC\<1,000/mm3 with a single temperature(temp) of \>38.3 degrees C or a sustained temp of ≥38 degrees C for more than one hour).Tox requiring dose omissions of \>5 days or significant \& deemed by the primary investigator(PI) \& sponsor(sp) to be dose limiting .
| Participants | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT) | 0 | 0 | 3 |
Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556).
| microgram per milliliter (µg/mL) | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| LY2940680:Cycle 1 Day 1 | 0.841 ± 8 | 1.81 ± 5 | 3.84 ± 29 |
| LY2940680:Cycle 1 Day 15 | 1.41 ± 51 | 3.10 ± 21 | 9.08 ± 40 |
| LSN3185556:Cycle 1 Day 1 | 0.925 ± 45 | 1.49 ± 8 | 3.02 ± 30 |
| LSN3185556:Cycle 1 Day 15 | 2.12 ± 84 | 4.10 ± 22 | 13.7 ± 50 |
Pharmacokinetics (PK): Area Under the Concentration time Curve From 0 to 24 Hours (AUC\[0-24\]) of LY2940680 and a Major Metabolite of LSN3185556.
| microgram*hour per milliliter(µg*h/mL) | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| LY2940680:Cycle 1 Day 1 | 7.96 ± 31 | 20.3 ± 22 | 43.1 ± 26 |
| LY2940680:Cycle 1 Day 15 | 14.7 ± 78 | 42.9 ± 40 | 142 ± 61 |
| LSN3185556:Cycle 1 Day 1 | 13.2 ± 48 | 24.6 ± 5 | 50.1 ± 30 |
| LSN3185556:Cycle 1 Day 15 | 31.8 ± 126 | 79.7 ± 15 | 235 ± 48 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size (\<10 millimeter \[mm\] short axis). PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.
| Participants | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR]) | 0 | 1 | 0 |
Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin.
| percentage change | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| Pharmacodynamic (PD): Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin | 92.73 ± 0.928 | 89.24 ± 2.096 | 92.86 ± 8.053 |
Collected over Baseline to End of Study (Up To 2.45 Years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: 100 mg LY2940680 | — | 0/3 (0%) | 3/3 (100%) |
| Cohort 2: 200 mg LY2940680 | — | 0/3 (0%) | 3/3 (100%) |
| Cohort 3: 400 mg LY2940680 | — | 4/13 (30.8%) | 13/13 (100%) |
| Event | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/13 |
| Pericardial effusionCardiac disorders | 0/3 | 0/3 | 1/13 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 1/13 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/3 | 1/13 |
| Cerebral infarctionNervous system disorders | 0/3 | 0/3 | 1/13 |
| Cerebrovascular accidentNervous system disorders | 0/3 | 0/3 | 1/13 |
| Event | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 |
|---|---|---|---|
| DysgeusiaNervous system disorders | 3/3 | 2/3 | 8/13 |
| FatigueGeneral disorders | 1/3 | 0/3 | 10/13 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 1/3 | 10/13 |
| NauseaGastrointestinal disorders | 1/3 | 1/3 | 9/13 |
| ConstipationGastrointestinal disorders | 2/3 | 1/3 | 2/13 |
| HaematuriaRenal and urinary disorders | 0/3 | 2/3 | 0/13 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/3 | 2/3 | 1/13 |
| RashSkin and subcutaneous tissue disorders | 2/3 | 0/3 | 0/13 |
| VomitingGastrointestinal disorders | 0/3 | 1/3 | 7/13 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 1/3 | 5/13 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 7.02 | 72.0 ± 4.36 | 60.7 ± 11.93 | 62.9 ± 10.95 |
| Sex: Female, Male(Participants) | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 0 | 3 |
| Male | 1 | 2 | 13 | 16 |
| Race (NIH/OMB)(Participants) | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 13 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: 100 mg LY2940680 | Cohort 2: 200 mg LY2940680 | Cohort 3: 400 mg LY2940680 | Total |
|---|---|---|---|---|
| Japan | 3 | 3 | 13 | 19 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Aug 2013, a primary completion of May 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2019, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY2940680